Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
07 Novembro 2024 - 8:10AM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the
Company) today announced that it has appointed Craig Johnson to its
Board of Directors (the Board) to support its next phase of growth.
Mr. Johnson has more than 30 years of experience serving in senior
financial management roles and governing companies in the
biotechnology industry. He previously served as a director of Ardea
Biosciences, Inc., Adamis Pharmaceuticals Corporation, Decipher
Biosciences, Inc., La Jolla Pharmaceutical Company, Odonate
Therapeutics, Inc. and Mirati Therapeutics, Inc. He currently
serves as a director of Heron Therapeutics, Inc. His biography can
be found here.
The Company also announced that Dr. Robert T. Foster has retired
from the Board.
“As part of our ongoing efforts to ensure that the Board
includes the most qualified professionals to help guide the Company
to maximize shareholder value, we are pleased to welcome Craig to
the Board,” stated Kevin Tang, Chair of the Board. “The Board would
also like to thank Robert for his many contributions to the
Company.”
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical
company focused on delivering therapies to people living with
autoimmune diseases with high unmet medical needs. In January 2021,
the Company introduced LUPKYNIS® (voclosporin), the first
FDA-approved oral therapy dedicated to the treatment of adult
patients with active lupus nephritis. Aurinia is also developing
AUR200, a differentiated, potential best-in-class therapy for
autoimmune diseases that targets both BAFF (B-cell Activating
Factor) and APRIL (A Proliferation-Inducing Ligand).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241107383259/en/
Media & Investor Inquiries: Andrea Christopher
Corporate Communications & Investor Relations Aurinia
Pharmaceuticals Inc. achristopher@auriniapharma.com
General Investor Inquiries: ir@auriniapharma.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
